BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32988862)

  • 1. Genomic Database Analysis for Head and Neck Cancer Prevention Targets: MTOR Signal Transduction Pathway.
    Koenigsberg C; Ondrey FG
    Anticancer Res; 2020 Oct; 40(10):5417-5421. PubMed ID: 32988862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA 744-3p promotes MMP-9-mediated metastasis by simultaneously suppressing PDCD4 and PTEN in laryngeal squamous cell carcinoma.
    Li JZ; Gao W; Lei WB; Zhao J; Chan JY; Wei WI; Ho WK; Wong TS
    Oncotarget; 2016 Sep; 7(36):58218-58233. PubMed ID: 27533461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
    Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
    Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.
    Riquelme I; Tapia O; Espinoza JA; Leal P; Buchegger K; Sandoval A; Bizama C; Araya JC; Peek RM; Roa JC
    Pathol Oncol Res; 2016 Oct; 22(4):797-805. PubMed ID: 27156070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
    Marquard FE; Jücker M
    Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression profile of the PI3K-AKT-mTOR pathway in head and neck squamous cell carcinoma: Data from Brazilian population.
    Marques AEM; Borges GA; Viesi do Nascimento Filho CH; Vianna LMS; Ramos DDAR; Castilho RM; Squarize CH; Guerra ENS
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Apr; 133(4):453-461. PubMed ID: 35153184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
    Day TA; Shirai K; O'Brien PE; Matheus MG; Godwin K; Sood AJ; Kompelli A; Vick JA; Martin D; Vitale-Cross L; Callejas-Varela JL; Wang Z; Wu X; Harismendy O; Molinolo AA; Lippman SM; Van Waes C; Szabo E; Gutkind JS
    Clin Cancer Res; 2019 Feb; 25(4):1156-1164. PubMed ID: 30420444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes
    Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A
    Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
    Liu F; Zhao X; Qian Y; Zhang J; Zhang Y; Yin R
    Biomed Pharmacother; 2017 Dec; 96():229-237. PubMed ID: 28987947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing of RHEB inhibits cell proliferation and promotes apoptosis in colorectal cancer cells via inhibition of the mTOR signaling pathway.
    Tian Y; Shen L; Li F; Yang J; Wan X; Ouyang M
    J Cell Physiol; 2020 Jan; 235(1):442-453. PubMed ID: 31332784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
    Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
    Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that
    Izumi H; Wang Z; Goto Y; Ando T; Wu X; Zhang X; Li H; Johnson DE; Grandis JR; Gutkind JS
    Mol Cancer Ther; 2020 Jul; 19(7):1562-1571. PubMed ID: 32430488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
    Slattery ML; Herrick JS; Lundgreen A; Fitzpatrick FA; Curtin K; Wolff RK
    Carcinogenesis; 2010 Sep; 31(9):1604-11. PubMed ID: 20622004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diet and colorectal cancer: analysis of a candidate pathway using SNPS, haplotypes, and multi-gene assessment.
    Slattery ML; Lundgreen A; Herrick JS; Caan BJ; Potter JD; Wolff RK
    Nutr Cancer; 2011 Nov; 63(8):1226-34. PubMed ID: 21999454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.
    Lasota J; Kowalik A; Felisiak-Golabek A; Zięba S; Wang ZF; Miettinen M
    Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):54-58. PubMed ID: 28777148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AKT3 is a key regulator of head and neck squamous cell carcinoma.
    Takahashi H; Rokudai S; Kawabata-Iwakawa R; Sakakura K; Oyama T; Nishiyama M; Chikamatsu K
    Cancer Sci; 2021 Jun; 112(6):2325-2334. PubMed ID: 33811778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.
    Pfisterer K; Fusi A; Klinghammer K; Knödler M; Nonnenmacher A; Keilholz U
    Head Neck; 2015 Apr; 37(4):471-8. PubMed ID: 24421178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.